A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503)
Related Posts
Shah PD, Yeremian S, Forte E, Park D, Choi E, Qi J, Nguyen A, Akhtari M. EXPRESS: A Meta-analysis Reporting the Most Common Infectious Complications[...]
Long GV, Khattak MA, Gogas HJ, Schadendorf D, Arance A, Carlino MS, Rutkowski P, Rivalland G, Ribas A, Mehnert JM, Ott PA, Dummer R, Queirolo[...]
Garassino MC, Ahn MJ, Schick M, Kapil A, Paz-Ares L, Lisberg A, Johnson ML, Pérol M, Shimizu T, Heist R, Spira A, Okamoto I, Girard[...]